TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01925612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
Study: NCT02330237

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03292562

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Discontinue NCPAP after weaning pressures
Description: After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
Study: NCT00077493

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immunotoxin therapy
Description: tested for immunogenicity to CAT-8015 before each cycle and at end of study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: monoclonal antibody therapy
Description: administered intravenously over 30 minutes.
Study: NCT02980757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide 120 mg MR Tablets
Study: NCT00350792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV), every 21 days x 6 cycles
Study: NCT02980757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide 120 mg MR Tablets Formula B
Study: NCT00350792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
Study: NCT01925612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study: NCT01330095

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Bifidobacterium bifidum
Description: Administration of Bifidobacterium bifidum to very low birth weight infants

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Bifidobacterium bifidum
Description: Administration of Bifidobacterium bifidum to very low birth weight infants
Study: NCT01495039

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nystatin
Description: Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nystatin
Description: Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
Study: NCT04708808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy
Description: cases will randomly assigned to receive music therapy group with routine care, plus music given via headphone, or assign to control group with no music given.
Study: NCT01093313

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attention training
Study: NCT00991809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfentanil
Description: 15 mcg/kg IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: 25 mg IM
Study: NCT01925612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
Study: NCT03057912

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TALEN
Description: TALEN gel consists of TALEN plasmid, C32-447, Poloxmer 407 and distilled water as solvent.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CRISPR/Cas9
Description: CRISPR/Cas9 gel consists of CRISPR/Cas9 plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
Study: NCT00834886

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Capsules, 3 mg, once every night

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Capsules, 3 mg, once every night

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bright light
Description: Bright light therapy 10.000 lux by Miljølys AS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bright light
Description: Bright light therapy 10.000 lux by Miljølys AS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo red light
Description: Red light 400 lux as placebo light

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo red light
Description: Red light 400 lux as placebo light

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsule
Description: Capsules containing 3 mng rice flour, once every night

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Capsules containing 3 mng rice flour, once every night
Study: NCT01014949

Intervention type: OTHER
Group type: OTHER
Intervention: Coronary microcirculation assessment
Description: Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014 coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine \[140 ug/kg/min\] to induce steady state maximal hyperemia.
Study: NCT00992732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HQK-1004
Description: 1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir (may substitute with ganciclovir)
Description: 900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
Study: NCT03200093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vancomycin
Description: Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ora-Sweet 5mL taken by mouth once daily.
Study: NCT03979027

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfast: ready-to-eat-cereal and milk
Study: NCT03465176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy Blend
Description: The essential oil intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
Study: NCT03292562

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Discontinue NCPAP without weaning pressures
Description: After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
Study: NCT03465176

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo substance is an odorless vegetable oil derived from avocados.
Study: NCT00225147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human C1 Inhibitor
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human C1 Inhibitor
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline solution
Study: NCT01778400

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol ablation
Description: ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
Study: NCT00828997

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Prevenar vaccination
Description: vaccination with Prevenar vaccine in patients with arthritis
Study: NCT01184391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DEPAKOTE® Tablets, 500 MG
Description: 1 x 500 mg tablet, under fasting conditions
Study: NCT02725333

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Shoulder Stabilization
Description: Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
Study: NCT01184391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG
Description: 1 X 500 mg Tablet, under fasting conditions.
Study: NCT03073525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vigil
Description: The Vigil vaccine is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters.

Intervention type: DRUG
Group type: OTHER
Intervention: Atezolizumab
Description: Atezolizumab was prepared and administered at the FDA approved dose and schedule as described in the U.S. Package Insert (USPI). The initial dose was administered over one hour and if well tolerated, subsequent infusions may have been administered over 30 minutes.~Atezolizumab in formulation F03 (1200 mg per vial) was administered in 250 mL 0.9% NaCl IV infusion bags and infusion lines equipped with 0.2 μm in-line filters.
Study: NCT04377269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping and Bandaging
Description: Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon
Study: NCT01848093

Intervention type: OTHER
Intervention: sputum collection
Description: collecting of spontaneous sputum from the patient
Study: NCT00538057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X & GW642444M
Description: study drug
Study: NCT01760070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid knife
Description: Use Hybrid knife in ESD procedure
Study: NCT02167087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node mapping
Description: Through transabdominal access via laparoscopic ports indocyanine green solution is injected around the tumor (25 mg indocyanine green dissolved in 9 ml sterile water and 1 ml 20% human albumin). This is done by the construction of two small boluses of 0.5 mL each into the colonic wall just orally and anally to the tumor margin, but not within the tumor itself. When the bolus is injected the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner.
Study: NCT03543150

Intervention type: DRUG
Intervention: BOTOX
Description: BOTOX injections will be administered to eligible subjects with diagnosis of spasmodic dysphonia. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
Study: NCT03008603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XACT Robotic System
Description: The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
Study: NCT01760070

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IT knife
Description: Use IT knife in ESD procedure.
Study: NCT04868344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG003
Description: Administered intravenously
Study: NCT02735603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl/bupropion HCl
Description: Naltrexone HCl/bupropion HCl extended-release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl/bupropion HCl
Description: Naltrexone HCl/bupropion HCl extended-release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl/bupropion HCl
Description: Naltrexone HCl/bupropion HCl extended-release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl/bupropion HCl
Description: Naltrexone HCl/bupropion HCl extended-release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl/bupropion HCl
Description: Naltrexone HCl/bupropion HCl extended-release tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone HCl/bupropion HCl
Description: Naltrexone HCl/bupropion HCl extended-release tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Naltrexone/bupropion placebo-matching tablets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Naltrexone/bupropion placebo-matching tablets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Naltrexone/bupropion placebo-matching tablets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Naltrexone/bupropion placebo-matching tablets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Naltrexone/bupropion placebo-matching tablets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Naltrexone/bupropion placebo-matching tablets.
Study: NCT04466020

Intervention type: OTHER
Intervention: Qualitative research interviews to be conducted
Description: None. Qualitative research interviews to be conducted
Study: NCT02735603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin tablet.
Study: NCT00244010

Intervention type: DEVICE
Group type: OTHER
Intervention: Allogeneic stem cell transplant
Description: Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
Study: NCT04377269

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Taping and Bandaging
Description: Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taping and Bandaging
Description: Ankle taping: a hard preventive Zinc oxide tape was used. The taping procedures consisted of three separate steps. 1) included the application of the anchor tape. 2) application of the stirrup tape. The stirrup tape was performed two times by holding the foot in a neutral position and the tape is placed as it passed through the medial side of the ankle (under the foot), just over the heel area (posterior one-third of the foot) and up along the lateral side of the ankle. Bandaging: standard 10cm width elastic bandage used. The bandage wrapped around the ankle joint in the form of an 8-figure. Bandage started from the forefoot, moving diagonally upwards and steeply enough to go well above the heel to end around the lower calf area to form an anchor. Then, it moved diagonally down across the mid-foot. Placebo: 10cm long tape was applied on the lateral side of the leg, just above the lateral malleolus and aligned with peroneus longus tendon
Study: NCT03024255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000 gel, 5%
Description: BBI-4000 gel, 5% applied once to each axilla daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000 gel, 10%
Description: BBI-4000 gel, 10% applied once to each axilla daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-4000 gel, 15%
Description: BBI-4000 gel, 15% applied once to each axilla daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo)
Description: Placebo, applied once to each axilla daily